Program

Program Wednesday, May 20, 2015

7:15 AM - 8:15 AM
EDUCATIONAL SYMPOSIA
7:15 AM - 8:15 AM
Room: Grand Ballroom, Salon H (Level 5)
BRIDGING THE REAL-WORLD EVIDENCE (RWE) DIVIDE WITH PAYERS AND INTEGRATED DELIVERY NETWORKS (IDNS): MAKING PHARMA A TRUE COLLABORATOR IN EVIDENCE

(Sponsored by IMS Health)

8:30 AM - 9:30 AM
ISSUE PANELS - SESSION IV
Health Policy Development Using Outcomes Research Issues
8:30 AM - 9:30 AM
Room: Grand Ballroom, Salon G (Level 5)

IP16: DO STATE MEDICAID FORMULARIES WORSEN OUTCOMES FOR PATIENTS WITH MENTAL ILLNESS?

Moderator:

Seth A. Seabury, PhD, Associate Professor of Research, Department of Emergency Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA

Panelists:

Dana P. Goldman, PhD, Leonard D. Schaeffer Chair & Director, Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA

Anupam B. Jena, MD, PhD, Assistant Professor of Health Care Policy and Medicine, Harvard Medical School, Boston, MA, USA

Darius N. Lakdawalla, PhD, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, School of Pharmacy, University of Southern California, Los Angeles, CA, USA


8:30 AM - 9:30 AM
Room: Grand Ballroom, Salon A-F (Level 5)

IP17: VALUE-BASED FORMULARY DESIGN (VBFD): IS PREMERA A VOICE CRYING IN THE WILDERNESS?

Moderator:

Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA

Panelists:

Dan Danielson, MS, RPh, Pharmacy Manager, Clinical Services, Premera Blue Cross, Mountlake Terrace, WA, USA

Edmund J. Pazella, MD, MPH, National Medical Director, Pharmacy Management, Aetna, Inc., Hartford, CT, USA

John Graham, Pharm. D, Vice President & VEO, CVM-NS, Global Value Evidence and Outcomes - RD Projects Clinical Platforms & Sciences, GlaxoSmithKline, King of Prussia, PA, USA


8:30 AM - 9:30 AM
Room: Grand Ballroom, Salon H (Level 5)

IP18: COMPETITIVE BIDDING FOR THERAPEUTICALLY-EQUIVALENT BRANDED PHARMACEUTICALS: PROMISE OR THREAT?

Moderator:

Josephine A. Mauskopf, PhD, MHA, MA, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

Panelists:

David W. Miller, PhD, Senior Vice President, Global Market Access, Biogen Idec, Maidenhead, UK

Susan Hogue, PharmD, MPH, Senior Director, Value Insight and Access Strategy, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

Economic Outcomes Research Issues
8:30 AM - 9:30 AM
Room: Grand Ballroom, Salon I (Level 5)

IP19: READY FOR RISK SHARING? CHALLENGES AND IMPLICATIONS FOR MANUFACTURERS

Moderator:

Kim White, MBA, Senior Consultant, Numerof & Associates, St. Louis, MO, USA

Panelists:

Bryan Gilpin, SM, Director, Customer Solutions & International Operations, Boston Scientific Corporation, Marlborough, MA, USA

Sherry Thornton, Vice President, Healthcare Alliances, Medtronic, Inc., Memphis, TN, USA

Don Liss, MD, Vice President, Clinical Programs and Policy, Independence Blue Cross, Philadelphia, PA, USA

Patient-Reported Outcomes & Patient Preference Research Issues
8:30 AM - 9:30 AM
Room: Grand Ballroom, Salon K-L (Level 5)

IP20: APPLICATION OF PROMIS TOOLS IN PHARMACEUTICAL AND DEVICE INDUSTRY STUDIES: ARE WE MOVING THE WHEEL FORWARD?

Moderator:

Stacie Hudgens, MA (AbD), Managing Partner, Clinical Outcomes Solutions, Tucson, AZ, USA

Panelists:

David Cella, PhD, Professor, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Ashley Slagle, PhD, Clinical Outcome Assessment Qualification Scientific Coordinator & Study Endpoints Reviewer, U.S. Food and Drug Administration, Silver Spring, MD, USA

Rajiv Mallick, PhD, Senior Director, Health Economics and Outcomes Research, BTG International Inc., West Conshohocken, PA, USA

8:30 AM - 2:45 PM
RESEARCH POSTER PRESENTATIONS - SESSION V
9:30 AM - 9:45 AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V
9:45 AM - 11:00 AM
WELCOME & THIRD PLENARY SESSION
Room: Grand Ballroom, Salon A-F (Level 5)
WELCOME
Adrian Towse, MA, MPhil bio
2014-2015 ISPOR President and Director, Office of Health Economics, London, UK
9:45 AM - 11:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
THIRD PLENARY SESSION: BIG DATA, BIG SYSTEMS, AND BETTER EVIDENCE: WHAT PROGRESS?
What could the growing interest in big data mean for health delivery systems and patients? This session will explore the challenges for incorporating big data into health system decisions and processes. A number of related questions will be explored. Can big data be used to improve evidence and clinical decision making? Is there a need for new analytical approaches? How will these developments affect patients?
Moderator: Adrian Towse, MA, MPhil bio
Director, Office of Health Economics, London, UK
Speaker: Ari Caroline bio
Chief Analytics Officer, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Speaker: Ami Ehlenberger bio
Director of Client Solutions, IBM Watson Group, Philadelphia, PA, USA
Speaker: Paul Wallace, MD bio
Chief Medical Officer & Senior Vice President, Clinical Translation, Optum Labs and Chair, Board of Directors, AcademyHealth, Cambridge, MA, USA
11:00 AM - 11:30 AM
ISPOR 20th INTERNATIONAL MEETING RESEARCH PRESENTATION AWARDS
11:30 AM - 1:45 PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V
11:45 AM - 12:45 PM
EDUCATIONAL SYMPOSIA
11:45 AM - 12:45 PM
Room: Grand Ballroom, Salon H (Level 5)
THE REAL WORLD: HOW INTEGRATED DATA IS USED TO IMPROVE PATIENT CARE

(Sponsored by Optum)

12:45 PM - 1:45 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION V
1:45 PM - 2:45 PM
WORKSHOPS - SESSION IV
Health Policy Development Using Outcomes Research
1:45 PM - 2:45 PM
Room: Grand Ballroom, Salon H (Level 5)
W22: HOW TO DESIGN AN ANALYTIC STRATEGY FOR EVIDENCE GENERATION FOR DECISION MAKERS
Discussion Leaders:

Sean D. Sullivan, PhD, MSc, RPh, Professor & Dean, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

Omar Dabbous, MD, MPH, Head of Value Evidence Analytics, GlaxoSmithKline, King of Prussia, PA, USA

Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA bio

Rafael Alfonso-Cristancho, MD, PhD, MSc, Director, Value Evidence Analytics, Research and Development, GlaxoSmithKline (GSK), King of Prussia, PA, USA

Use of Real World Data
1:45 PM - 2:45 PM
Room: Grand Ballroom, Salon J (Level 5)
W23: INTEGRATED LONGITUDINAL DATA: HOW DYNAMIC DATA COLLECTION CAN BIAS ESTIMATORS AND POSSIBLE SOLUTIONS
Discussion Leaders:

Henry J. Henk, PhD, Vice President & Principal Consultant, Optum, Eden Prarie, MN, USA

William H Olson, PhD, Leader, Research and Analysis Strategy, Janssen Scientific Affairs, LLC, Titusville, NJ, USA

Clinical Outcomes Research
1:45 PM - 2:45 PM
Room: Grand Ballroom, Salon I (Level 5)
W24: A PRACTICAL APPROACH TO UNDERSTAND THE CONCEPTS AND METHODS USED TO ASSESS HETEROGENEITY AND INCONSISTENCY IN NETWORK META-ANALYSES
Discussion Leaders:

Varun Ektare, BPharm, MPH, Senior Analyst, Pharmerit International, Bethesda, MD, USA

Dipen Patel, PhD, Director, HEOR, Pharmerit International, Bethesda, MD, USA

Berhanu Alemayehu, PhD, Director, Outcomes Research, CORE, Primary Care Merck, Gaithersburg, MD, USA

Sonya J Snedecor, PhD, Executive Director, Health Economics, Pharmerit International, Bethesda, MD, USA

Economic Outcomes Research
1:45 PM - 2:45 PM
Room: Grand Ballroom, Salon G (Level 5)
W25: MODELING TREATMENTS FOR RARE DISEASES: METHODOLOGIC CONSIDERATIONS, CHALLENGES & POTENTIAL SOLUTIONS
Discussion Leaders:

Michele Kohli, PhD, Director, Health Economics and Outcomes Research, Optum, Burlington, ON, Canada

Debbie L. Becker, MSc, Director, Health Economics and Outcomes Research, Optum, Burlington, ON, Canada

Milton C Weinstein, PhD, Henry J. Kaiser Professor of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, MA, USA

Pablo Lapuerta, MD, Executive Vice President & Chief Medical Officer, Lexicon Pharmaceuticals, Princeton, NJ, USA

Patient-Reported Outcomes & Patient Preference Research
1:45 PM - 2:45 PM
Room: Grand Ballroom, Salon K-L (Level 5)
W26: BACK TO THE FUTURE: LEARNING THE LESSONS IN VALUING EQ-5D-3L HEALTH STATES
Discussion Leaders:

Paul Kind, Professor, Academic Unit of Health Economics, University of Leeds, Leeds, UK

Roisin Adams, PhD, Deputy Head, National Centre for Pharmacoeconomics, Dublin, Ireland

Mônica Viegas, PhD, Professor, Economics Department, Center for Regional Development and Planning, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

2:45 PM - 3:00 PM
BREAK & EXHIBITS VIEWING - SESSION V
3:00 PM - 4:00 PM
WORKSHOPS - SESSION V
Health Policy Development Using Outcomes Research
3:00 PM - 4:00 PM
Room: Grand Ballroom, Salon I (Level 5)
W27: WHEN BETTER THINGS HAPPEN TO A GOOD MODEL: A DEVELOPMENT OF THE DIFFERENCE IN DIFFERENCES (DD) MODEL INTO A DIFFERENCE IN DIFFERENCES IN DIFFERENCES IN DIFFERENCES (DDDD) MODEL WHEN ANALYZING THE EFFECT OF AN INTERVENTION
Discussion Leaders:

Hemant Phatak, PhD, Group Director, Global Health Economics & Outcomes Research, Bristol-Myers Squibb Company, Princeton, NJ, USA

Ya-Chen Tina Shih, PhD, Professor of Health Economics, & Section Chief, Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Yanru Qiao, MS, Data Analyst, Department of Clinical Pharmacy, The University of Tennessee College of Pharmacy, Memphis, TN, USA

Junling Wang, PhD, Associate Professor, Department of Clinical Pharmacy, The University of Tennessee College of Pharmacy, Memphis, TN, USA


3:00 PM - 4:00 PM
Room: Grand Ballroom, Salon K-L (Level 5)
W28: HORIZON SCANNING – IDENTIFYING AND ESTIMATING FUTURE IMPACT OF EMERGING INNOVATIONS ON U.S. HEALTH CARE
Discussion Leaders:

Elise Berliner, PhD, Director, Health Technology Assessment, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, MD, USA

Karen Schoelles, MD, SM, Project Director, AHRQ Healthcare Horizon Scanning System and Director, ECRI Institute Evidence-based Practice Center, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA

Marcus Lynch, PhD, Senior Horizon Scanning Analyst, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA

Jalpa A. Doshi, PhD, Associate Professor of Medicine & Director, Economic Evaluations Unit, Center for Evidence-based Practice and Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, General Internal Medicine, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA

Use of Real World Data
3:00 PM - 4:00 PM
Room: Grand Ballroom, Salon G (Level 5)
W29: STRATEGIES FOR ASSESSING THE PATIENT-LEVEL ECONOMIC IMPACT OF CANCER DIAGNOSIS
Discussion Leaders:

Veena Shankaran, MD, MS, Assistant Professor, Division of Medical Oncology, University of Washington, Seattle, WA, USA

Amy Davidoff, PhD, MS, Senior Research Scientist, Cancer Prevention and Control, Yale School of Public Health, New Haven, CT, USA

Donatus Ekwueme, PhD, Senior Health Economist, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Chamblee, GA, USA

Economic Outcomes Research
3:00 PM - 4:00 PM
Room: Grand Ballroom, Salon J (Level 5)
W30: WARRANTING BUDGET PREDICTABILITY THROUGH MANAGED ENTRY AGREEMENTS AND INSURANCE-BASED MECHANISMS
Discussion Leaders:

Olivier Ethgen, MSc, PhD, Adjunct Professor, Health Economics, University of Liege, Liege, Belgium

Augustin Terlinden, MSc, Health Economist, BLUE ANTIDOTE, Tervuren, Belgium

Patient-Reported Outcomes & Patient Preference Research
3:00 PM - 4:00 PM
Room: Grand Ballroom, Salon H (Level 5)
W31: DEVELOPMENTS AND COMMUNICATION SINCE THE ISSUANCE OF FDA’S GUIDANCE TO INDUSTRY ON PATIENT-REPORTED OUTCOMES: THEN AND NOW
Discussion Leaders:

Brooke Witherspoon, BA, Associate Director, Research & Operations, Endpoint Outcomes, Boston, MA, USA

Somali Misra Burgess, PhD, CEO & Research Director, Strategic Outcomes Services, Mission Viejo, CA, USA

Paivi Miskala, MSPH, PhD, Founder, ProCon Global, LLC, Rockville, MA, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.